Member Info for Yorkshirepragma

https://igmbio.com/

https://igmbio.

$6.2bn deal with Sanofi
GLA

https://finance.yahoo.com/news/regeneron-regn-buy-checkmate-pharmaceuticals-151603843.html

https://www.biopharmadive.com/news/abbvie-genmab-epcoritimab-lymphoma-data/622128/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202022-04-20%20BioPharma%20Dive:%20Commercialization%20%5Bissue:41166%5D&utm_term=BioPharma%20Dive:%20Commercialization

Apologies …fast Track!
Note many are ‘amelioration’ treatment to avoid side effects.
GLA

https://www.fda.gov/media/150966/download

And FDA fast rack is feasible ….
GLA

Let’s hope the efficacy of Avactas new tech primarily assists folk.
Secondary to that is a cancer treatment market share of several £bn.
My guess is potential aquisitive market interest will now be very high, and after results from prog. emerge ,this will rapidly lead to ‘offers’.
Commentary made as an old bold Zenacite…
No wonder Alastairs upbeat…
GLA
.

https://www.businesswire.com/news/home/20220411006012/en/GSK-Reaches-Agreement-to-Acquire-Late-Stage-Biopharmaceutical-Company-Sierra-Oncology-For-1.9bn

And reflecting on current business value ( for those who’ve not seen it) ,a benchmark purchase by GSK, for a ‘lesser target range’ co,without the bells and whistles Affimers offer.
Co must be in £ 2-3bn range at present?, and as soon as data emerges upwards of this.
GLA

https://www.fiercebiotech.com/biotech/biopharma-ma-2022-different-animal-drugmakers-coffers-lined-17t
Reasonable stateside review but…
Earlier stage dev. Buyout is a possibility, $1.7tn in coffers
GLA

Results of current trails mid year….thereafter?
GLA

With % attainable of MSC market …
https://www.grandviewresearch.com/industry-analysis/mesenchymal-stem-cells-market
Ditto % cancer treatment…of several $bn
Ditto% ‘other areas’…
Such progress will be sustainable to say the least ( and do a lot of good)
Chance of success in RR terms must be 60-70% ( if not higher ) on current Sci. Progress presented recently
GLA

Paul’s enthusiasm ,well placed.
GLA

https://www.alliedmarketresearch.com/vascular-graft-market

Being a ‘Fly on the wall’ @ conference might be of value…who knows in the ‘close Pharma world ‘ ,what info of interest might emerge…serendipity.
GLA

Successful 1b/2 stage dev. ~ + $ 2bn val.
Robust enhancement beyond this….~ ?
GLA

https://www.nature.com/articles/d43747-022-00033-5
Gla

https://twitter.com/MylesMcNulty/status/1466441080120000519

The above as has been said, really really worth ‘weighing’.
GLA

https://www.biopharmadive.com/news/biotech-pharma-deals-merger-acquisitions-tracker/604262/

Could attract some attention then?
GLA

A straightforward look at Biocytogen Exec. Will tell you that these are s USA centric quality educated team, likely to deliver considerable benefits herein.
I look forward to their contribution,to enhance an already sophisticated and game changing scientific contribution to health care globally.
GLA

That’s AS dialogue yest. …see slide on this and it’s timed accordingly
Apps